RxDoctor Payments Data

Dandan Li, MD

Family Medicine · Richmond, VANPI 1720366917

Payments from drug & device makers

$414in general payments, 2019–2025

Across 23 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$210
  • Pfizer$39
  • GSK$37
  • Novo Nordisk$35
  • Merck$26
  • Currax Pharmaceuticals LLC$25
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$38994%
  • Education$256%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)8$210
Pfizer3$39
GSK3$37
Novo Nordisk3$35
Merck2$26
Currax Pharmaceuticals LLC1$25
Lilly USA, LLC2$23
Amgen1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$414 in reported general payments places this provider in the 55th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$124,425
Medicare patients
170
Services billed
3,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide30$36,654
LinzessLinaclotide23$18,438
WegovySemaglutide11$16,821
CreonLipase/Protease/Amylase15$16,056
Breo ElliptaFluticasone/Vilanterol12$4,804
SynthroidLevothyroxine Sodium50$3,516
YuvafemEstradiol19$3,291
Valsartan52$1,977
Levothyroxine Sodium159$1,740
Estradiol24$1,656
Rosuvastatin Calcium103$1,572
Estradiol (Twice Weekly)Estradiol14$1,571
PaxlovidNirmatrelvir/Ritonavir11$1,429
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide37$1,225
ValacyclovirValacyclovir Hcl28$1,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Synthroid$210$38,01088 claims
Lilly USA, LLCMounjaro$23$36,65430 claims
Novo NordiskWegovy$35$16,82111 claims
GSKBreo Ellipta$37$4,80412 claims
PfizerPaxlovid$39$1,42911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →